Pharmaceutical Technology on MSN

J&J announces Tecvayli-Darzalex combo approval from FDA for multiple myeloma

The approval was supported by data from the ongoing Phase III MajesTEC-3 study.
The American Journal of Managed Care

Ushering in a New Combination-Driven Era in MCL

Early ASH 2025 data suggest sonrotoclax is a promising therapy in MCL, supporting a broader shift toward chemo-free, combination-based strategies—particularly for patients with BTK ...
Medical Xpress

New research identifies promising drug combination for multiple myeloma treatment

New research from the Royal College of Surgeons in Ireland has found that venetoclax, a medication currently approved for leukemia, provides benefits for patients with multiple myeloma when used in ...
Healio

Combination induces durable responses in advanced multiple myeloma

Please provide your email address to receive an email when new articles are posted on . Researchers observed responses at all dose levels, with the recommended phase 2 regimen linked to durable ...
Morningstar

Tec-Dara Combination Offers Substantial Improvement Over Standard Second-Line Therapies for Relapsed or Refractory Multiple Myeloma

The trial is the first to test a bispecific monoclonal antibody as early as the first relapse after initial treatment for multiple myeloma. Based on the findings, researchers suggest the combination ...
Nasdaq

Erasca Announces First Patient Dosed in HERKULES-3, a Phase 1b/2 Gastrointestinal Cancer Master Protocol Evaluating ERAS-007 in Multiple Combinations

ERAS-007, a potential best-in-class ERK1/2 inhibitor, will be evaluated initially in combinations that could address over half of patients with colorectal cancer SAN DIEGO, Sept. 22, 2021 (GLOBE ...